Susceptible Microorganism: Linezolid has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections, as described in this section.
Aerobic and facultative Gram-positive microorganisms: Enterococcus faecium (vancomycin-resistant strains only), Staphylococcus aureus (including methicillin-resistant strains), Streptococcus agalactiae, Streptococcus pneumoniae (Penicillin-susceptible strains only), Streptococcus pyogenes.
The following in vitro data are available, but their clinical significance is unknown. At least 90% of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for linezolid. However, the safety and effectiveness of linezolid in treating clinical infections due to these microorganisms have not been established in adequate and well-tolerated clinical trials.
Aerobic and facultative Gram-positive microorganisms: Enterococcus faecalis (including vancomycin-resistant strains) Enterococcus faecium (vancomycin-resistant strains), Staphylococcus epidermidis (including methicillin-resistant strains), Staphylococcus haemolyticus, Streptococcus pneumoniae (penicillin-resistant strains), Viridans group streptococci.
Aerobic and facultative Gram-negative microorganisms: Pasteurella multocida.
Linezolid has no clinical activity against Gram-negative against pathogens and is not indicated for the treatment of: Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.
Infectious Diseases: LINEZOLID is used for treatment of patients with the following infections: Nosocomial pneumonia; Community-acquired pneumonia (including concurrent bacteremia); Complicated skin and skin structure infections (including diabetic foot infections, without concomitant osteomyelitis); Uncomplicated skin and skin structure infections; Vancomycin-resistant Enterococcus faecium infections (including concurrent bacteremia).
Other Services
Country
Account